Titanium particles may explain why antibiotics fail against dental implant infections

Dental implants have given tens of millions of people something dentures never could: a full set of fixed and fully functioning teeth. Unfortunately, 10% to 20% of implant patients eventually experience an aggressive jawbone infection called peri-implantitis. Antibiotics usually fail to stop the infection for reasons that researchers have not understood until now.

Study uncovers a surprising culprit

A recent study in PNAS Nexus by researchers with the Rutgers School of Dental Medicine has found that bacteria corrode implants, causing them to shed microscopic titanium particles into the surrounding tissue. Those particles hijack the immune cells sent to clear the infection and lock them into a state of inflammation that destroys the jawbone they are supposed to protect.

Working with human tissue samples, cultured human immune cells and a genetically engineered mouse model, the team pinpointed a specific calcium channel in the body’s bacteria-eating macrophages that the titanium particles activate. Switching that channel off in mice prevented the disease. The result is the first credible drug target for a condition that affects up to one in five implant recipients and costs the global health system more than a billion dollars a year.

“For the first time, we show why all the antibiotic treatments that work around teeth do not work around implants,” said Georgios Kotsakis, the study’s senior author and the assistant dean for clinical research at the dental school. “Now that we know the cause, we can start developing therapeutics.”

Why implants behave differently than teeth

Peri-implantitis has long been a puzzle because it initially looks like its counterpart in natural teeth, which is called periodontitis and begins with the same oral bacteria. In patients with natural teeth, antibiotics and routine cleaning resolve the infection. In patients with implants, the same drugs against the same bacteria succeed less than half the time, while the bone underneath continues to disappear.

Most research over the past 20 years has focused on the bacteria. Members of Kotsakis’s lab took a different approach and began looking at the implants. Bacteria living on the implant surface produce acidic biofilms that slowly corrode the titanium, releasing billions of particles smaller than a red blood cell. The same shedding can occur during routine cleaning, especially with instruments that dentists typically use on natural teeth.

Inside the gum, those particles get coated with a bacterial toxin called lipopolysaccharide. To the immune system, they suddenly look like enormous, indigestible bacteria. Macrophages, a type of white blood cell that surrounds and kills microorganisms, engulf them but cannot digest metal. The cells become trapped in a hyperinflammatory state, pumping out signaling molecules including interleukin-1 beta, an inflammatory protein also implicated in rheumatoid arthritis and Alzheimer’s disease.

How titanium particles hijack immunity

That inflammation eats away at bone. Worse, the immune cells lose their ability to deal with the original infection. In the lab, macrophages exposed to titanium particles took up less than half as many bacteria as unexposed cells.

“These particles are little magnets that attract the bacterial toxin, and they hijack the immune system, preventing it from clearing bacteria,” said Kotsakis. “You have a perfect storm that defies antibiotics.”

Team members traced the cascade to a calcium channel (a specialized, pore-forming protein structure within cell membranes) called TRPC1. In mice engineered without it, the immune cells handled the same titanium-plus-bacteria challenge normally: Abscesses were dramatically smaller, inflammatory cytokines dropped, and bacterial clearance was restored.

New treatment avenues and safer cleanings

Members of Kotsakis’s group are now testing drug candidates that target the same pathway in human cells.

For people who already have implants, the most useful finding may be a quieter one. The strongest known protective factor is regular professional cleaning, but the kind of cleaning matters. Until roughly a decade ago, many dentists scraped implants with the metal scalers used on teeth, a method the Rutgers lab and others have shown can itself corrode the implant and accelerate the disease. Nonabrasive techniques are now standard.

Unprecedented view inside live stem cells reveals aging process and loss of regenerative capacity

Scientists have developed a powerful new technique that allows them to observe how individual cells manufacture proteins during aging, offering an unprecedented glimpse into the hidden molecular activity of stem cells in living tissue. As a result of the research, conducted at the Institute for Regenerative Medicine in Switzerland, scientists were able to observe aging unfold inside individual epidermal stem cells.

What scientists saw was the intricate choreography within stem cells and how those molecular dance steps slow and change with age. The team of Swiss scientists has concluded that the process of aging reshapes how skin stem cells manufacture proteins. The findings are published in the journal Molecular Cell.

Protein production impacted

The study revealed that aging epidermal stem cells undergo distinct shifts in their protein-production capabilities, changes that could help explain declining regenerative capacity of these cells in older tissue.

Using an advanced form of single-cell ribosome profiling in an animal model, investigators were able to map the “translational landscapes” of aging skin—essentially tracking how stem cells control protein production over time. Translational landscapes refer to the overall pattern of protein production.

Mechanistically, ribosome profiling allows scientists to determine which messenger RNAs are actively being translated into proteins inside cells at a given moment. The profiling technique not only allowed researchers to eavesdrop on living cells but led to the discovery that aging stem cells in the skin become reprogrammed.

“Stem cells are characterized by two features: their ability to self-renew throughout life and to differentiate into other cell types,” wrote Dr. Clara Duré, lead author of the new research, who—along with a team of investigators—has opened a new window of understanding into stem cells throughout various stages of life.

Stem cells are blank slates

Because stem cells are essentially blank slates capable of morphing into any cell type, their biological role and fate differ significantly from other cell types. By tracking them through stages of life, it’s possible to see how they impact processes such as inflammation and immunity, the team found.

Paradoxically, even during youth, stem cells are not high-energy cells that keep their ribosomes busy with the production of proteins. Instead, these workbenches in stem cells where proteins are constructed exist as relatively quiescent structures.

“Somatic stem cells are characterized by their low overall protein-synthesis rates, a feature implicated in driving their stemness,” Duré continued, noting that the term “stemness,” refers to the cells’ capacities for self-renewal and remaining unspecialized until needed.

Both of these functions are closely linked to their precise regulation of gene expression. Somatic stem cells exhibit a unique signature marked by high ribosome biogenesis and a low protein synthesis rate.

Aging reshapes translational capacity

Yet, exactly how aging reshapes the translational landscape of stem cells had remained poorly understood until the new research helped illuminate what was occurring within stem cells themselves.

The ribosome profiling technique allowed the Zurich-based team to determine which messenger RNAs were being actively translated into proteins inside cells at any given moment, and across different stages of aging in the mouse model, which was used in the study.

“Somatic stem cells exhibit a unique signature marked by high ribosome biogenesis and low protein synthesis rates, a feature that is implicated in independently driving their stemness, regardless of cellular proliferation, cell cycle, or total mRNA content,” Duré and colleagues noted in the study.

Several takeaways from the research suggest that the potent new technique for studying stem cells in living tissue could eventually permit research on aging tissue in unprecedented detail, illuminating why these cells lose regenerative power over time.

“Our study focuses on the epidermis. This tissue is highly heterogeneous, including epidermal stem cells, differentiated keratinocytes, hair follicle cells, and resident immune cells such as macrophages, dendritic cells, and T cells,” Duré concluded. “We note, however, that extending the single-cell ribosome profiling protocol to additional tissues may require further optimization.”

Advancing detection of genome-edited crops in food mixtures

Researchers from Sciensano, partner of the DARWIN project, have published a new paper in npj Science of Food addressing one of the key scientific and regulatory challenges linked to genome-edited (GE) organisms, their reliable detection and identification in complex food mixtures.

In the European Union, GMOs in the food chain are currently regulated under Regulations (EC) No. 1829/2003 and No. 1830/2003 to ensure safety, traceability, and consumer freedom of choice. Since 2018, genome-edited organisms have also fallen under this legislation. However, detecting and unambiguously identifying these organisms remains particularly challenging, as they can differ from their wild-type counterparts by only one or a few single-nucleotide variations (SNVs).

The publication investigates for the first time the use of high-throughput sequencing combined with adaptive sampling (AS) to selectively enrich a target species of interest in food mixtures. This approach aims to reduce matrix complexity and subsequently facilitate the detection and identification of GE lines.

As a proof-of-concept, the researchers analyzed soybean mixtures containing trace levels of genome-edited or wild-type rice using three sequencing modes: standard sequencing, adaptive sampling enriching rice, and adaptive sampling depleting soybean. The resulting sequencing data were then used to evaluate the effectiveness of, on the one hand, rice enrichment in food mixtures and, on the other hand, reliable identification of each tested rice line through the detection of their respective genetic fingerprints.

The study represents a promising first step toward facilitating the detection and identification of genome-edited organisms in the food chain, supporting future traceability and regulatory compliance efforts within the European Union framework.

Your own personal Farmville: This VR greenhouse lets users monitor crops remotely

You’ve probably heard of Stardew Valley or Farmville, video games where you manage a virtual farm. Now, what if you could monitor real plants from the comfort of your home? Thanks to new research at Binghamton University, State University of New York, that’s becoming a reality.

Creating virtual replicas of real farms

Engineers at Binghamton University, State University of New York have developed a system that creates “digital twins” of real farms, allowing users to walk through fully interactive virtual spaces and observe actual plants in real time—technology that could make farming more accessible for older adults and people with disabilities.

“This gives users the experience of walking through a greenhouse they already know without physically being there,” said Anwar Elhadad, assistant professor of electrical and computer engineering at Binghamton University.

The paper, “Immersive Digital Twin Framework for Reliability Monitoring of IoT Sensor Nodes Using Mixed Reality,” was presented at the 35th Microelectronics Design and Test Symposium.

Making farm monitoring more accessible

While sensors are crucial for monitoring modern-day farms, 2D dashboards lack the contextual information that comes from being onsite, said Elhadad. This system lets users explore your greenhouse as if they’re actually there. The technology could be especially useful for those who can’t adequately access their farms.

“This project is designed for accessibility. So if someone is elderly and can’t walk around the farm or the greenhouse, they can use this interactive setup and see the data, see how everything is working,” said Mohamed Gallai, a Ph.D. student in electrical and computer engineering at Binghamton University and lead author of the paper.

How the mixed reality system works

Plants are photographed and placed in the virtual environment as 3D objects. A microcontroller placed in the soil or at each plant monitors vital information, such as humidity, temperature, and gas levels and sends the data to the virtual system in real time. Using goggles, users can walk around the greenhouse and see the plants, interact with them, and monitor data.

The system provides real-time sensor data on key metrics such as temperature, humidity, and light.

“You can imagine 10 or 20 plants, each with its own miniaturized monitoring system feeding data into the VR space. And you get to log in, inspect plant by plant, depending on how many sensors you actually installed in your space,” said Elhadad.

Potential classroom and future applications

In addition to improved accessibility, this system could also be used for educational purposes. For example, students in biological and agricultural sciences might use it to study plants in a hands-on, interactive environment.

The researchers noted that the project is still in the early stages, and based on demand, they could add more features to the VR space in the future.

Ph.D. students Azaz-Ur-Rehman Nasir and Ofelia Huerta also contributed to this research.

Kailera walks path paved by Lilly in post-IPO ‘catalyst-rich period’

Kailera Therapeutics is advancing a pipeline of weight loss medicines that mirrors Eli Lilly’s: an injectable GLP-1/GIP dual agonist like Zepbound, an oral GLP-1 like Foundayo and a triple-G therapy like retatrutide.

After a record-breaking $625 million IPO, Kailera Therapeutics will tread a relatively safe road as the biotech’s trifecta of obesity drugs follow in the footsteps of one of the industry’s leading weight-loss players.

“We view Kailera’s broad GLP-1-based pipeline as largely de-risked through clinical and commercial validation from competitor programs, especially those from Eli Lilly,” William Blair told investors in a Wednesday note.

Kailera’s lead asset is ribupatide, a dual agonist of the GLP-1 and GIP receptors, much like Lilly’s mega-blockbuster Zepbound. Kailera is also advancing a small-molecule GLP-1 pill called KAI-7535 and a “triple-G” agonist dubbed KAI-4729—assets that work similarly to Lilly’s recently approved Foundayo and investigational retatrutide, respectively.

Despite the high bar that Lilly has set in the obesity market, there remains a place for Kailera, William Blair contended, noting that the company’s medicines could provide “options for patients with various weight-loss goals and across the full treatment journey.”

Kailera made a huge splash last month when it went public with a $625 million raise—the largest biotech IPO haul in history, topping Moderna’s $600 million from late 2018. Kailera launched in October 2024 with $400 million in starting capital and ex-China rights to a clutch of weight-loss assets from China’s Jiangsu Hengrui. Before going public, the biotech in October 2025 brought in $600 million in series B proceeds.

Now trading on the Nasdaq, Kailera is “heading into a catalyst-rich period” with clinical updates on the horizon for all of its obesity programs, according to William Blair.

On Wednesday, for instance, the biotech announced the initiation of a Phase 2b study testing higher doses of injectable ribupatide, with data expected next year. Ribupatide is also entering a broad Phase 3 weight-loss program called KaiNETIC. Initial findings are slated for 2028.

Kailera on Wednesday also provided data for its weight-loss pill KAI-7535 from a Phase 3 diabetes study conducted by Chinese partner Hengrui. At 32 weeks, patients taking the drug saw a 1.40% to 1.68% decrease in HbA1c levels, a measure of blood average sugar concentrations over the last two to three months. Placebo comparators saw a 0.06% drop in HbA1c.

Hengrui will report Phase 3 data for KAI-7535 in obesity later this year, Kailera said.

As for the triple-G drug, the biotech reported a mean weight reduction of 16% at 12 weeks, as compared with 5.4% in placebo counterparts, based on data from a Phase 1 study conducted in China. Kailera plans to initiate an early-stage program for KAI-4729 outside China, with data expected next year—where it will face high expectations set by Lilly’s retatrutide. The Big Pharma’s asset earlier this month elicited 28.3% weight reduction over 80 weeks.

“We anticipate 2027 to be a catalyst-rich year” for Kailera, William Blair analysts told investors on Wednesday, adding that the biotech is “positioned to be a strong contender in the obesity market.”

The long wait: biopharma job searches often take at least 6 months, BioSpace finds

More than half of biotech and pharma job seekers have been looking for their next opportunity for six months or longer, and more than a quarter have searched for over a year, according to a BioSpace LinkedIn poll. Job seekers share their frustrations.

Biopharma professionals hoping to get hired quickly probably need to be patient—and some of them very, very patient. A BioSpace LinkedIn poll this month found that 53% of respondents who are job hunting have been at it for at least six months and 27% for one year or longer.

A recent Monster survey showed similar results for the lengthier end of that timeline. It found that 25% of job seekers had been looking for work for over a year.

The BioSpace LinkedIn poll findings align with data from a survey late last year that informed the BioSpace 2026 U.S. Life Sciences Employment Outlook report. According to that data, 49% of unemployed respondents had been out of work for at least six months and 26% for more than a year.

Lengthy job searches can be challenging for biopharma professionals who need to quickly shore up their finances, regain health insurance or avoid long employment gaps. For some, the best option is taking positions they’re overqualified for. Biopharma professionals are increasingly turning to this form of underemployment, according to a BioSpace LinkedIn poll earlier this month. It found that 52% of respondents had recently accepted jobs they were overqualified for, up from 44% in March 2025.

Ghosting, ghost jobs lead list of job search frustrations

The length of time it takes to find biopharma work is not the only downside of job searches these days. To understand the pain points, BioSpace invited biotech and pharma professionals to share the most frustrating part of their searches via SurveyMonkey.

Most respondents called out job ghosting, which happens when applicants don’t receive follow-up communication from recruiters or prospective employers after direct contact, typically a screening or interview. One biopharma professional wrote, “Even a generic one would be appreciated, otherwise it feels like I’m sending resumes into a void.”

Not knowing if job postings are fake, a reference to ghost jobs, was another frustration respondents mentioned.

Job ghosting and ghost jobs are not new issues for biopharma professionals. They were the most frequently selected choices in an early 2025 BioSpace LinkedIn poll about candidates’ biggest job hunt pet peeves, at 35% and 34%, respectively.

Some of this month’s SurveyMonkey respondents also cited skill or degree requirements for positions as another frustration. One criticized jobs that require “extremely specific” experience, even for entry-level jobs, while another commented on a bachelor’s degree being required “when experience is all that is needed.”

Another respondent took issue with the way prospective employers view skills. They wrote that even when the skills required for jobs are transferable, applicants can be boxed into a specific therapeutic area rather than get a chance to grow or develop know-how in a different one.

In a sign of how competitive the biopharma job market has become, one survey respondent noted frustration with the response rate on applications. Their rate is 2% to 4% now compared to 10% to 20% 18 months ago, they wrote.

Another sign of the market’s competitiveness is continuing layoffs. With Takeda’s May 13 earnings presentation disclosure that it will cut about 4,500 employees during fiscal year 2026, May has become the worst month this year for biopharma layoffs, according to BioSpace tallies.* As of May 26, the number of people biotech and pharma companies cut or planned to cut hit 6,956, surging past the previous highest monthly total of 3,713 in February.

*Layoff numbers exclude contract development and manufacturing organizations, contract research organizations, tools and services businesses and medical device firms. To tally the cuts, BioSpace compiles data for known workforce reductions. The number of employees affected is identified or estimated primarily through information in company press releases, Worker Adjustment and Retraining Notification (WARN) Act notices, SEC filings and other media outlets’ reports or via confirmation from company officials.

Breast tumors use sugar coating to evade immunity, opening potential immunotherapy path

Immunotherapies such as so-called checkpoint inhibitors activate the body’s own immune system to fight cancer cells and have revolutionized the treatment of many types of tumor. In breast cancer, however, these therapies are often only of limited effectiveness. An international research team led by the Medical University of Vienna has now identified a previously underestimated mechanism by which breast tumors evade the immune system.

The findings, published in the journal Nature Communications, also provide a new starting point for improving the effectiveness of immunotherapies in breast cancer.

Sialylation is the name given to the biochemical process that the research team led by Stefan Mereiter (Department of Obstetrics and Gynecology, MedUni Vienna) and Josef Penninger (Clinical Institute of Laboratory Medicine, MedUni Vienna) has identified as a central mechanism of immune suppression in breast cancer.

This involves a specific sugar modification on the surface of tumor cells that impairs communication between cells and the immune system.

“We were able to show that around two-thirds of all breast tumors exhibit increased sialylation. In these cases, significantly fewer T-cells—i.e., immune cells that fight cancer cells—were detectable in the tumor tissue,” reports lead author Mereiter. Analyses of patient cohorts comprising a total of 136 breast cancer cases confirmed this link.

Targeted inhibition of the mechanism

In detail, the researchers discovered that sialylation, among other things, enhances the effect in the blood of the immunomodulatory growth factor G-CSF produced by cancer cells. This leads to an increased recruitment of immunosuppressive cells into the tumor, which in turn prevents cytotoxic, i.e. cell-killing, T-cells from efficiently penetrating the tumor tissue.

At the same time, sialylation makes tumor cells less recognizable to existing T cells, thereby allowing them to evade the immune system. In preclinical research models, however, the targeted pharmacological inhibition of sialylation led to T cells spreading throughout the tumor again and being able to combat it more effectively.

“More activated cytotoxic T cells reach the tumor, while at the same time, immunosuppressive neutrophil cells decrease,” explains study leader Josef Penninger.

Breast cancer is the most common cancer in women. Immunotherapies, such as so-called checkpoint inhibitors, which are designed to activate the body’s own immune system to defend against cancer cells, are only of limited effectiveness against this type of tumor.

The current study results provide both a possible explanation and a solution for this.

“Our study shows that therapeutically blocking sialylation causes even tumor models that were previously resistant to treatment to respond to immunotherapies. Our findings therefore suggest that the targeted modulation of tumor sialylation could be a promising new approach to overcoming immune-suppressive mechanisms within the tumor and thus significantly improving the efficacy of immunotherapies in breast cancer,” said Mereiter and Penninger.

The findings are now to be further investigated in additional studies within the newly established research group led by Mereiter at the Department of Obstetrics and Gynecology at MedUni Vienna, with the aim of developing future therapies.

Why caffeine can sabotage deep sleep even when you still get eight hours

Evening coffee has sparked controversy for years. Some people fall asleep without difficulty, while others toss and turn for half the night. However, a growing body of research suggests the question of whether coffee makes it harder to fall asleep may be too simplistic. What appears to matter far more is what happens in the brain during sleep.

Scientists studying the effects of caffeine on sleep are increasingly turning to EEG, or electroencephalography, a method used to record the brain’s electrical activity. Thanks to EEG, it is possible to observe not only sleep duration or moments of awakening, but also the biological quality of sleep itself.

“EEG allows scientists to see not only whether a person is sleeping, but also how the brain is sleeping. Classical sleep assessment measures sleep duration and its stages, whereas quantitative EEG analysis reveals more subtle changes, such as reduced slow-wave activity, which is an important marker of sleep depth and its restorative character,” said Prof. Donata Kurpas of the Department of Nursing at Wroclaw Medical University.

Slow waves are one of the key components of deep sleep, the phase responsible for bodily regeneration, restoration of energy resources, and proper brain function.

Caffeine may cause ‘shallow’ sleep

The research published in Nutrients shows the effects of caffeine do not always manifest as shorter sleep or difficulty falling asleep. Much more often, the changes concern the quality of nighttime rest.

“Caffeine may shorten sleep or make it more difficult to fall asleep. However, even when sleep duration appears normal, it may reduce slow-wave activity and shift the EEG pattern toward a more wakeful brain,” Kurpas said.

This means the body may spend eight hours in bed, but the brain may fail to fully regenerate. People are often unaware of this.

“The subjective feeling of having slept well does not always correspond to what researchers observe in neurophysiological recordings. A person may fall asleep without major difficulty and not remember awakenings, while the brain may display fewer features of deep sleep,” she added.

Why does coffee affect everyone differently?

One of the most interesting conclusions emerging from research is the enormous individual variability in response to caffeine. Genetics, metabolic rate, age, stress levels and chronic fatigue all play a role.

For some individuals, even coffee consumed in the morning may be problematic. “It is not only about coffee consumed just before bedtime. For some people, the total amount of caffeine consumed during the day and whether the body has enough time to metabolize it before nightfall may also be important,” Kurpas said.

This is particularly important information for people engaged in intellectual work, athletes and anyone who regularly uses caffeine to improve performance and concentration.

Energy is borrowed from the body

Caffeine improves alertness and reduces the sensation of fatigue, but experts point out its effects may sometimes resemble borrowing energy at the expense of nighttime regeneration.

“If caffeine helps a person function during the day while simultaneously worsening the quality of nighttime recovery, a vicious circle may develop: greater fatigue, greater need for stimulation and poorer sleep,” Kurpas said.

For this reason, modern sleep research is increasingly moving away from simple questions about sleep duration and focusing instead on how the brain functions during nighttime rest.

“Caffeine is neither good nor bad. It is a biologically active substance whose effects depend on dose, time of day, age, lifestyle, sleep quality, stress burden and individual sensitivity,” she said.

DNA ‘nicks’ make for safer, more precise genetic analysis

Researchers at Cornell University have developed a safer and more precise way to study how genes function in living tissues by refining a recently developed CRISPR-based genetic technique in fruit flies, enabling researchers to better study how genes contribute to development and disease.

Published in the Proceedings of the National Academy of Sciences, the work highlights a new method that replaces the harsh DNA cuts used in traditional CRISPR analysis with gentler cuts known as “nicks.”

According to Chun Han, associate professor in the Department of Molecular Biology and Genetics in the College of Agriculture and Life Sciences (CALS) and the Weill Institute for Cell and Molecular Biology, the approach still allows scientists to study how genes function in living tissues, but with far less unintended cellular damage and greater control over the experiment.

CRISPR is a gene-editing technology that allows scientists to precisely cut DNA to study how genes function. One method built around CRISPR, called MAGIC, creates small groups of altered cells inside an otherwise normal organism. Researchers can then observe how specific genes affect development, cell behavior, and disease.

The original MAGIC technique relies on creating double-strand breaks, which are cuts made through both strands of DNA, to trigger the genetic changes needed for the analysis.

“We mainly wanted to improve the MAGIC technique by finding a way to avoid the toxicity associated with Cas9, which acts as the ‘molecular scissors’ in the CRISPR gene-editing system,” said Han, who led the study with Cornell doctoral student Yifan Shen and undergraduate student Ann Yeung, who is now a doctoral student at Harvard.

The original MAGIC system uses the CRISPR enzyme Cas9 to cut both strands of DNA to induce recombination between homologous chromosomes, chromosome pairs inherited from each parent, in developing cells. The recombination helps create homozygous cells (cells containing two identical copies of a gene derived from a single parent) that researchers need to study gene function, but the DNA breaks can also unintentionally rearrange chromosomes.

“In our original design of MAGIC, we used Cas9 to induce double-strand breaks (DSBs) in developing cells,” Han said. “But those DNA breaks can be highly detrimental to chromosomes during cell division, harming or killing cells.”

To address the problem, the researchers turned to “nickases,” modified versions of Cas9 that cut only one strand of DNA instead of both.

“Nickases are derived from Cas9 but carry mutations that allow them to cut only one strand of DNA,” Han said. “Without producing double-strand breaks, nickases do not damage cells in the same way and can still be used with the MAGIC technique.”

One of the study’s most unexpected findings was that even a single DNA nick could trigger the recombination needed for the MAGIC technique to work, Han said.

The researchers also found that the exact pattern of DNA nicking strongly influenced how often recombination of DNA occurred, offering scientists new ways to tune experiments for different research needs.

The advance could help researchers study genes with greater confidence by reducing the risk that experimental damage itself alters cell behavior. Cleaner, more reliable genetic tools could help researchers better study how genes contribute to development and disease, Han said.

“Our ability to study biology is restrained by the limit of our tools,” he said. “Avoiding the unintended DNA damage can make researchers more confident in using this technique and interpreting their results.”

Han said the new nickase-based system, combined with a recently developed genome-wide MAGIC toolkit, could expand use of the technique across the fruit fly research community and eventually beyond it.

“Drosophila, the fruit fly, is often the birthplace of new genetic techniques,” Han said. “But many genetic techniques invented in Drosophila later found their ways into other organisms.”

Advancing detection of genome-edited crops in food mixtures

Researchers from Sciensano, partner of the DARWIN project, have published a new paper in npj Science of Food addressing one of the key scientific and regulatory challenges linked to genome-edited (GE) organisms, their reliable detection and identification in complex food mixtures.

In the European Union, GMOs in the food chain are currently regulated under Regulations (EC) No. 1829/2003 and No. 1830/2003 to ensure safety, traceability, and consumer freedom of choice. Since 2018, genome-edited organisms have also fallen under this legislation. However, detecting and unambiguously identifying these organisms remains particularly challenging, as they can differ from their wild-type counterparts by only one or a few single-nucleotide variations (SNVs).

The publication investigates for the first time the use of high-throughput sequencing combined with adaptive sampling (AS) to selectively enrich a target species of interest in food mixtures. This approach aims to reduce matrix complexity and subsequently facilitate the detection and identification of GE lines.

As a proof-of-concept, the researchers analyzed soybean mixtures containing trace levels of genome-edited or wild-type rice using three sequencing modes: standard sequencing, adaptive sampling enriching rice, and adaptive sampling depleting soybean. The resulting sequencing data were then used to evaluate the effectiveness of, on the one hand, rice enrichment in food mixtures and, on the other hand, reliable identification of each tested rice line through the detection of their respective genetic fingerprints.

The study represents a promising first step toward facilitating the detection and identification of genome-edited organisms in the food chain, supporting future traceability and regulatory compliance efforts within the European Union framework.

error: Content is protected !!